Free Trial
→ Why More Investors Are Using Family Trusts to Protect Their Wealth (From SmartAsset) (Ad)tc pixel
NASDAQ:BBLG

Bone Biologics 5/12/2025 Earnings Report

Bone Biologics logo
$2.15 +0.02 (+0.94%)
Closing price 09/24/2025 04:00 PM Eastern
Extended Trading
$2.15 0.00 (0.00%)
As of 08:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Bone Biologics EPS Results

Actual EPS
-$1.92
Consensus EPS
-$2.88
Beat/Miss
Beat by +$0.96
One Year Ago EPS
N/A

Bone Biologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bone Biologics Announcement Details

Quarter
Date
5/12/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bone Biologics' next earnings date is estimated for Thursday, November 13, 2025, based on past reporting schedules.

Conference Call Resources

Bone Biologics Earnings Headlines

Wall Street Zen Downgrades Bone Biologics (NASDAQ:BBLG) to Sell
September 22 at 2:32 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30338817
Short Interest in Bone Biologics Corp. (NASDAQ:BBLG) Declines By 73.6%
September 14, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30326474
Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
September 25 at 2:00 AM  |  SmartAsset (Ad)
Bone Biologics Corp. (BBLG) Stock Price Today - WSJ
September 6, 2025  |  wsj.comhttps://www.wsj.com/market-data/quotes/us/BBLG
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
September 4, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250904789999/en/bone-biologics-ceo-issues-letter-to-stockholders-highlighting-company-update-and-outlook/
Bone Biologics Announces Closing of $5.0 Million Public Offering
June 30, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250630002956/en/bone-biologics-announces-closing-of-5.0-million-public-offering/
See More Bone Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bone Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bone Biologics and other key companies, straight to your email.

About Bone Biologics

Bone Biologics (NASDAQ:BBLG), Inc. (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects. Early-stage clinical studies and preclinical investigations are underway to assess safety, tolerability and preliminary efficacy in these high-need segments. The company collaborates with leading orthopedic surgeons and academic centers to design protocols and gather real-world insights that may inform future pivotal trials.

Founded in the late 2010s and headquartered in New Jersey, Bone Biologics has assembled a leadership team with extensive experience in regenerative medicine, cell therapy manufacturing and orthopedic clinical development. The company maintains partnerships with contract development and manufacturing organizations to scale its cell production processes, while engaging regulatory consultants to support filings with health authorities. As a dedicated cell therapy innovator, Bone Biologics aims to address significant unmet needs in bone repair and establish new standards for patient outcomes in orthopedic care.

View Bone Biologics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles